Lantern Pharma (LTRN) Stock News

Lantern Pharma (NASDAQ: LTRN) reports a remarkable clinical outcome from its Phase 2 HARMONIC trial, where a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) achieved a complete response using LP-300 with standard chemotherapy. The patient, who had previously failed three treatment lines including Keytruda, radiation, and Tagrisso, showed a 57% tumor reduction initially, followed by complete response in lung and adrenal gland lesions. After 21 treatment cycles over nearly two years, the patient maintains the response with no significant adverse reactions. This success is particularly significant for never-smokers with NSCLC, a growing patient population representing a $4+ billion market opportunity. Never-smoking NSCLC cases have increased from 15% in the 1970s to 33% in the 2000s, marking the fifth leading cause of cancer-related deaths globally.

Lantern Pharma (NASDAQ: LTRN) presented promising preclinical data for LP-184 in treating atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer. The data, presented at SNO's Pediatric Conference by Johns Hopkins researchers, showed significant survival improvements in mouse models: 345% increase (89 vs 20 days) in the CHLA06 model and extended survival in the BT37 model (98 vs 68 days). LP-184 demonstrated potent anti-tumor activity across multiple ATRT subtypes, with IC50 values of 17.5-161 nM, strong blood-brain barrier penetrance, and no apparent toxicity. This data validates Lantern's FDA Rare Pediatric Disease Designation and supports their planned pediatric clinical trial, expected to begin in late 2025 or early 2026, following completion of ongoing adult solid tumor trials.

Lantern Pharma (NASDAQ: LTRN) reported Q1 2025 financial results and key developments. The company is nearing completion of LP-184 Phase 1a trial enrollment with 62-65 patients by June 2025. Their LP-300 HARMONIC Trial in never-smoker NSCLC patients showed promising preliminary results with 86% clinical benefit rate and 43% objective response rate. The company's RADR® AI platform expanded to 200 billion oncology-focused data points, with new modules for ADC development. Financial position remains stable with $19.7 million in cash and equivalents as of March 31, 2025, providing runway through May 2026. Q1 2025 showed reduced net loss of $4.5 million ($0.42/share) compared to $5.4 million ($0.51/share) in Q1 2024. R&D expenses decreased to $3.3 million from $4.3 million year-over-year, while G&A expenses remained stable at $1.5 million.

Lantern Pharma (NASDAQ: LTRN) has received FDA clearance for its IND application amendment to begin a Phase 1b/2 clinical trial of LP-184 in non-small cell lung cancer (NSCLC). The trial will evaluate LP-184 in combination with immune checkpoint inhibitors (nivolumab and ipilimumab) in patients with KEAP1 and/or STK11 mutations and low PD-L1 expression. LP-184, developed using Lantern's AI platform RADR®, is a synthetically lethal small molecule that shows promise in treating this specific patient population, which currently has limited treatment options and a median survival of just 15 months. The targeted market opportunity exceeds $2 billion annually. Preclinical studies show LP-184's effectiveness correlates with PTGR1 expression levels, which are elevated in about 35% of lung cancer patients, particularly those with KEAP1 mutations.

Lantern Pharma (NASDAQ: LTRN), an AI-driven pharmaceutical company focused on developing targeted cancer therapies, has scheduled its first quarter 2025 operating and financial results webcast for Thursday, May 15, 2025, at 9:00 a.m. ET. The company's CEO, Panna Sharma, along with other management team members, will discuss Q1 2025 results and provide updates on upcoming milestones, clinical trials, and developments of their proprietary RADR® AI and machine learning platform. The webcast will be available for replay on the company's investor relations website after the call.

Lantern Pharma (LTRN) has received FDA clearance for its IND application to begin a Phase 1b/2 clinical trial of LP-184 in Triple Negative Breast Cancer (TNBC). The trial will evaluate LP-184 through two approaches: a monotherapy arm with approximately 30 advanced-stage TNBC patients, and a combination therapy with olaparib for second-line TNBC patients with BRCA1/2 alterations. LP-184, developed using Lantern's AI platform RADR®, is a novel small molecule that targets DNA damage in cancer cells. The drug previously received FDA Orphan Drug Designation (2023) and Fast Track Designation (2024) for TNBC treatment. The trials will be conducted in the US, India, and Nigeria, targeting regions with high TNBC incidence. The global TNBC market opportunity exceeds $4 billion annually, with over 300,000 new cases diagnosed worldwide each year.

Lantern Pharma (NASDAQ: LTRN) reported its Q4 and full-year 2024 results, highlighting significant progress in its AI-driven oncology drug development programs. The HARMONIC™ trial for LP-300 showed an impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with expansion in Japan and Taiwan. LP-184 received two FDA Fast Track Designations for Glioblastoma and Triple Negative Breast Cancer, plus three Rare Pediatric Disease Designations.

The company's RADR® AI platform surpassed 100 billion oncology-specific data points in 2024. Financial results showed cash position of $24.0 million as of December 31, 2024. Q4 net loss was $5.9 million ($0.54 per share), compared to $4.2 million ($0.39 per share) in Q4 2023. Full-year 2024 net loss per share was $1.93 versus $1.47 in 2023.

Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer therapy development company, has scheduled its fourth quarter and fiscal year 2024 financial results webcast for Thursday, March 27th, 2025, at 4:30 PM ET. The presentation will be led by President and CEO Panna Sharma, accompanied by the management team.

During the webcast, management will discuss:

• Q4 and full-year 2024 operating and financial results
• Upcoming milestones and clinical trials
• Development updates on the RADR® AI and machine learning platform

The company develops targeted cancer therapies using its proprietary RADR® AI platform and has multiple clinical-stage drug programs in development.

Lantern Pharma (NASDAQ: LTRN) announced the publication of its PCT patent application for a novel machine learning solution predicting blood-brain barrier (BBB) permeability. The technology has shown exceptional performance, processing up to 100,000 molecules per hour with industry-leading accuracy, with Lantern's AI algorithms holding five of the top eleven positions on the Therapeutic Data Commons Leaderboard.

The proprietary technology integrates advanced molecular representation techniques with synthetic data augmentation, processed by machine learning algorithms through Lantern's RADR® AI platform. The company's subsidiary, Starlight Therapeutics, plans to implement this technology for STAR-001 development. The PCT application allows Lantern to pursue worldwide patent protection for 20 years from filing, with expedited review initiated in the United States.